Skip to content

Released Aug 8, 2016, after the close

10-Q filed Aug 8, 2016, 39 days after period end · 0001564590-16-023312

Q2 2016 · 10-Q
Revenue$1.03M+212.2% vs Q2 2015−22.3% vs Q1 2016
Net Income-$8.41MN/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.29N/M vs Q2 2015N/M vs Q1 2016
Operating Income-$8,004,000N/M
Operating Cash Flowderived-$7,504,000N/M
Free Cash Flowderived-$7,710,000N/M
Margins · derived
Operating margin-779.4%+1414.6 pt vs Q2 2015
Net margin-818.7%+1545.7 pt vs Q2 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2016Q2 2015Q2 2014Q2 2013
Revenue$1.03M$329.00K—$290.00K
Net Income-$8.41M-$7.78M-$6.07M-$5.53M
EPS Diluted-$0.29-$0.33-$0.30-$4.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR